Team:Penn/SurfaceDisplayOverview

Surface Display and Targeting

While engineering bacteria as a light-activated drug delivery system is novel and useful by itself, the targeting potential of our light-activated bacterial therapeutic would be greatly improved if the bacteria also could target specific cells. The goal of the second module of our system is to allow bacterial targeting to cancer cells. We sought to achieve this by displaying an engineered cancer cell binding protein on the surface of our E. coli. We successfully displayed DARPin H10-2-G3, an antibody-mimetic protein rationally evolved to picomolar affinity with HER2, a breast cancer biomarker. We verified that bacteria displaying this protein can selectively bind to breast cancer cells in vitro. This class of protein has not been displayed before on the surface of bacteria. Along the way, we developed a generalized BioBrick surface display system which allows future iGEM teams to display proteins of their choosing on the surface of bacteria.

Objectives

Our goals were twofold:

1. Achieve the first display of DARPin H10-2-G3 on the surface of E. coli and verify that the system targets cancer cells.
2. Create a generalized BioBrick surface display platform for other labs and iGEM teams.

Ice Nucleation Protein

We chose to use the Ice Nucleation Protein (Figure 1) as our surface display carrier protein. The Ice Nucleation Protein protein has been used to display enzymes [1], typically for biocatalysis applications (e.g. Edinburgh iGEM 2011). To make the protein a more manageable size, we truncated the protein to the N and C terminal domains only. The C terminal domain is displayed at the cell surface, while the N terminal domain remains in the outer membrane. We sought to apply this system to health/medicine by displaying DARPin H10-2-G3.

[1] Zahnd, C., Wyler, E., Schwenk, J. M., Steiner, D., Lawrence, M. C., McKern, N. M., Pecorari, F., et al. (2007). A designed ankyrin repeat protein evolved to picomolar affinity to Her2. Journal of molecular biology, 369(4), 1015–28. doi:10.1016/j.jmb.2007.03.028

DARPin H10-2-G3

The lab of Andreas Plueckthun at ETH Zurich has pioneered the development of Designed Ankyrin Repeat Protein (DARPin) technology. DARPins are engineered antibody-mimetic proteins consisting of 3-5 ankyrin repeat motifs. These proteins have been rationally evolved to high binding affinity with targets through ribosome display. In 2007, the group developed H10-2-G3 [2], a 14.7kDa DARPin evolved to 90pM affinity with the extracellular domain of HER2 (Figure 2).

[2] Zahnd, C., Wyler, E., Schwenk, J. M., Steiner, D., Lawrence, M. C., McKern, N. M., Pecorari, F., et al. (2007). A designed ankyrin repeat protein evolved to picomolar affinity to Her2. Journal of molecular biology, 369(4), 1015–28. doi:10.1016/j.jmb.2007.03.028